BIOMAT Database Logo BIOMAT Database Logo

BAY X1005, a new selective inhibitor of leukotriene synthesis: pharmacology and pharmacokinetics. 1993

R Müller-Peddinghaus, and R Fruchtmann, and H J Ahr, and B Beckermann, and K Bühner, and B Fugmann, and B Junge, and M Matzke, and C Kohlsdorfer, and S Raddatz
Pharma Research Center, Bayer AG, Wuppertal, Germany.

The enantiomer BAY X1005 [(R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid] potently inhibits LTB4 synthesis in isolated PMNL of various species (IC50 mumol/l, human 0.22, rat 0.026, mouse 0.039) and LTC4 synthesis in mouse macrophages (IC50 0.021 mumol/l). Due to high protein binding the in vitro potency for LTB4 synthesis inhibition in whole blood is lowered to 17 mumol/l as determined by RIA. BAY X1005 is selective for the 5-lipoxygenase pathway leaving 12-HETE and HHT unaltered, as determined in human whole blood. After oral application BAY X1005 inhibits edema formation and myeloperoxidase activity in the arachidonate-induced mouse ear inflammation test (ED50 48.7 and 7.9, respectively). Oral activity in the rat ex vivo is found in whole blood for LTB4 synthesis inhibition (ED50 11.8 mg/kg p.o.). BAY X1005 demonstrates a high bioavailability (f 86%) with a Cmax of 13 mg/l and t1/2 of 3.5 h in the rat at 10 mg/kg p.o. Thus, the pharmacodynamic, pharmacokinetic profile and safety aspects of the leukotriene synthesis inhibitor BAY X1005 allow testing in man for its therapeutic potential in inflammatory and allergic diseases.

UI MeSH Term Description Entries
D007975 Leukotriene B4 The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990) 5,12-HETE,5,12-diHETE,LTB4,Leukotriene B,Leukotriene B-4,Leukotrienes B,5,12 HETE,5,12 diHETE,B-4, Leukotriene,Leukotriene B 4
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D011804 Quinolines
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016859 Lipoxygenase Inhibitors Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. 5-Lipoxygenase Inhibitor,Lipoxygenase Inhibitor,12-Lipoxygenase Inhibitors,15-Lipoxygenase Inhibitors,5-Lipoxygenase Inhibitors,Arachidonate 12-Lipoxygenase Inhibitors,Arachidonate 15-Lipoxygenase Inhibitors,Arachidonate 5-Lipoxygenase Inhibitors,Inhibitors, Lipoxygenase,12 Lipoxygenase Inhibitors,12-Lipoxygenase Inhibitors, Arachidonate,15 Lipoxygenase Inhibitors,15-Lipoxygenase Inhibitors, Arachidonate,5 Lipoxygenase Inhibitor,5 Lipoxygenase Inhibitors,5-Lipoxygenase Inhibitors, Arachidonate,Arachidonate 12 Lipoxygenase Inhibitors,Arachidonate 15 Lipoxygenase Inhibitors,Arachidonate 5 Lipoxygenase Inhibitors,Inhibitor, 5-Lipoxygenase,Inhibitor, Lipoxygenase,Inhibitors, 12-Lipoxygenase,Inhibitors, 15-Lipoxygenase,Inhibitors, 5-Lipoxygenase,Inhibitors, Arachidonate 12-Lipoxygenase,Inhibitors, Arachidonate 15-Lipoxygenase,Inhibitors, Arachidonate 5-Lipoxygenase
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D066298 In Vitro Techniques Methods to study reactions or processes taking place in an artificial environment outside the living organism. In Vitro Test,In Vitro Testing,In Vitro Tests,In Vitro as Topic,In Vitro,In Vitro Technique,In Vitro Testings,Technique, In Vitro,Techniques, In Vitro,Test, In Vitro,Testing, In Vitro,Testings, In Vitro,Tests, In Vitro,Vitro Testing, In

Related Publications

R Müller-Peddinghaus, and R Fruchtmann, and H J Ahr, and B Beckermann, and K Bühner, and B Fugmann, and B Junge, and M Matzke, and C Kohlsdorfer, and S Raddatz
Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY x1005.
June 1994, European journal of pharmacology,
R Müller-Peddinghaus, and R Fruchtmann, and H J Ahr, and B Beckermann, and K Bühner, and B Fugmann, and B Junge, and M Matzke, and C Kohlsdorfer, and S Raddatz
Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes.
January 1996, The Journal of pharmacology and experimental therapeutics,
R Müller-Peddinghaus, and R Fruchtmann, and H J Ahr, and B Beckermann, and K Bühner, and B Fugmann, and B Junge, and M Matzke, and C Kohlsdorfer, and S Raddatz
Piriprost: a selective inhibitor of leukotriene synthesis.
January 1985, Advances in prostaglandin, thromboxane, and leukotriene research,
R Müller-Peddinghaus, and R Fruchtmann, and H J Ahr, and B Beckermann, and K Bühner, and B Fugmann, and B Junge, and M Matzke, and C Kohlsdorfer, and S Raddatz
(R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl] acetic acid (BAY x1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways.
February 1994, The Journal of pharmacology and experimental therapeutics,
R Müller-Peddinghaus, and R Fruchtmann, and H J Ahr, and B Beckermann, and K Bühner, and B Fugmann, and B Junge, and M Matzke, and C Kohlsdorfer, and S Raddatz
Effect of a novel leukotoriene synthesis inhibitor, BAY x1005, on the antigen-and LPS-induced airway hyperresponsiveness in guinea pigs.
February 1996, Prostaglandins,
R Müller-Peddinghaus, and R Fruchtmann, and H J Ahr, and B Beckermann, and K Bühner, and B Fugmann, and B Junge, and M Matzke, and C Kohlsdorfer, and S Raddatz
In vivo and in vitro actions of a new selective inhibitor of leukotriene C and D synthesis.
January 1983, Advances in prostaglandin, thromboxane, and leukotriene research,
R Müller-Peddinghaus, and R Fruchtmann, and H J Ahr, and B Beckermann, and K Bühner, and B Fugmann, and B Junge, and M Matzke, and C Kohlsdorfer, and S Raddatz
Dealing with time-dependent pharmacokinetics during the early clinical development of a new leukotriene B4 synthesis inhibitor.
July 2006, Pharmaceutical research,
R Müller-Peddinghaus, and R Fruchtmann, and H J Ahr, and B Beckermann, and K Bühner, and B Fugmann, and B Junge, and M Matzke, and C Kohlsdorfer, and S Raddatz
Knipholone, a selective inhibitor of leukotriene metabolism.
June 2006, Phytomedicine : international journal of phytotherapy and phytopharmacology,
R Müller-Peddinghaus, and R Fruchtmann, and H J Ahr, and B Beckermann, and K Bühner, and B Fugmann, and B Junge, and M Matzke, and C Kohlsdorfer, and S Raddatz
Zileuton, a leukotriene synthesis inhibitor in the management of chronic asthma. Clinical pharmacokinetics and safety.
January 1999, Clinical reviews in allergy & immunology,
R Müller-Peddinghaus, and R Fruchtmann, and H J Ahr, and B Beckermann, and K Bühner, and B Fugmann, and B Junge, and M Matzke, and C Kohlsdorfer, and S Raddatz
New selective histamine H1 agonists. Synthesis and pharmacology.
December 1990, Pharmaceutisch weekblad. Scientific edition,
Copied contents to your clipboard!